Psoriasis: Consensus on topical therapies

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 7, 2008, Pages 859-870

  Van De Kerkhof, P C M ^a   Barker, J ^b   Griffiths, C E M ^c   Kragballe, K ^d   Mason, J ^e   Menter, A ^f,g   Papp, K ^h,i  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e DURHAM UNIVERSITY   (United Kingdom)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ PROBITY MEDICAL RESEARCH   (Canada)

Author keywords

Compliance; Corticosteroids; Disease severity; Retinoids; Treatment; Vitamin D3

Indexed keywords

ANTIPSORIASIS AGENT; APSOR; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; DRUG VEHICLE; ETRETIN; METHOTREXATE; PIMECROLIMUS; PLACEBO; SALICYLIC ACID; STEROID; TACALCITOL; TACLONEX; TACROLIMUS; TAZAROTENE; UREA; VITAMIN D DERIVATIVE;

ATOPIC DERMATITIS; BRONCHOSPASM; BURNING SENSATION; CARCINOGENICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONSENSUS; CREAM; DESQUAMATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FINLAND; FOLLICULITIS; GEL; HUMAN; HYPERCALCEMIA; MEDICAL SPECIALIST; MESSINESS; MONOTHERAPY; MORNING DOSAGE; NAIL STAINING; OINTMENT; PATIENT COMPLIANCE; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS SEVERITY INDEX; PUVA; SIDE EFFECT; SKIN DISEASE; SKIN IRRITATION; SKIN ODOR; SKIN STAINING; TACHYPHYLAXIS; TERATOGENICITY;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CHOLECALCIFEROL; HUMANS; PATIENT COMPLIANCE; PSORIASIS; RETINOIDS; SEVERITY OF ILLNESS INDEX; VITAMINS;

EID: 45249092593     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02534.x     Document Type: Conference Paper

References (86)

1. Fredrickson T, Pettersson U. Severe psoriasis: Oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
2. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 2004; 51: 563-569.
3. Kirby B, Fortune DG, Bhusham M, Chalmers RJ, Griffiths CEM. The Salford Psoriasis Index: An holistic measure of psoriasis severity. Br J Dermatol 2000; 142: 728-732.
4. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
5. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CEM. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-583.
6. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-414.
7. Feldman Sr, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57: 81-83.
8. Fucks J, Nitschmann WN, Pacher L. The antipsoriatic compound anthralin influences bioenergetic parameters and redox properties of energy transducing membranes. J Invest Dermatol 1990; 94: 71-76.
9. van de Kerkhof PCM. Dithranol treatment for psoriasis: After 75 years still going strong. European J Dermatol 1992; 1: 79-88.
10. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis; a systemic review. Br J Dermatol 2003; 146: 351-364.
11. Kanzler MH, Gorulowski DC. Efficacy of topical 5% liquor carbonis detergens vs its emollient base in the treatment of psoriasis. Br J Dermatol 1993; 129: 310-314.
12. Tham SH, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131: 673-677.
13. Sharma V, Kaur I, Kumar B. Calcipotriol vs coal tar: A prospective randomized study in stuble psoriasis. Int J Dermatol 2003; 42: 834-838.
14. Kaur I, Saraswat A, Kumar B. Comparison of calcipotriol and coal tar in conjunction with sun exposure in chronic plaque psoriasis, a pilot study. J Dermatol 2001; 28: 448-450.
15. Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermato 1 2000; 114: 587-590.
16. Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O'Brien PC. Skin cancer in patients with psoriasis treated with coal tar. Arch Dermatol 1981; 117: 465-468.
17. Manghan WZ, Muller SA, Perry HO, Pittelkow MR, O'Brien PC. Incidence of skin cancers in patients with atopic dermatitis, treated with coal tar. A 25-year follow up study. J Am Acad Dermatol 1980; 3: 612-615.
18. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980; i: 732-735.
19. Mason JM, Mason AR, Cork M. Topical preparations for the treatment of psoriasis: A systemic review. B J Dermatol 2002; 146: 351-364.
20. Mason AR, Cork MJ, Dooley G, Edwards G, Mason JM. Topical Treatments for Plaque Psoriasis (Protocol for a Cochrane Review). The Cochrane Library, Issue 4. John Wiley & Sons, Ltd, Chicester, UK, 2004.
21. Gunther S. Incidence and degree of unwanted adverse effects of corticoids in childhood. Results of dermatological studies in children with chronic diseases in the age group of 1-15 years. Z Hautkr 1976; 51: 569-579.
22. Queille C, Pommarede R, Saurat JH. Efficacy vs systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984; 1: 246-253.
23. Bode HH. Dwarfism following long term topical corticosteroid therapy. J Am Med Assoc 1980; 244: 813-814.
24. Ruiz-Maldonado R, Zapata G, Lourdes R, Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child 1982; 136: 274-275.
25. Hill CJ, Rosenberg A Jr. Adverse effects from topial steroids. Cutis 1978; 21: 624-628.
26. Drake L, Dinehart SM, Farmer ER et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol 1996; 35: 615-619.
27. Fisher DA. Adverse effects of topical corticosteroid use. West J Med 1995; 162: 123-126.
28. Feiwel M, Kelly WF. Adrenal unresponsiveness associated with clobetasol propionate. Lancet 1974; 2: 112-113.
29. Champion RH. Treatment of psoriasis. Br Med J 1966; 2: 993-995.
30. Baker H, Ryan TJ. Generalised pustular psoriasis. Br J Dermatol 1968; 80: 771-793.
31. Baker H. Corticosteroids and pustular psoriasis. Br J Dermatol 1976; 94: 83-88.
32. Du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975; 111: 581-583.
33. Feldman SR. Tachyphylaxis to topical corticosteroids: The more you use them, the less they work. Clin Dermatol 2006; 24: 229-230.
34. Ponec M, de Hass C, Bachra BN, Poland MK. Effects of glucocorticosteroids on cultured human skin fibroblasts. Arch Dermatol Res 1979; 265: 219-227.
35. Miller JJ, Rolling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids. J Am Acad Dermatol 1999; 41: 546-549.
36. Weinstein GD, Koo JY, Krueger GG et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48: 760-767.
37. Weinstein GD. The management of psoriasis-tazarotene: The bottom line. Cutis 1998: 61 (2 Suppl.): 38-39. Review.
38. Langner A, Stapor W, Ambroziak M. Effficacy and tolerance of topical calcitriol 3 microgram/g in psoriasis treatment: A review of our experience in Poland. Br J Dermatol 2001; 144 (Suppl. 58): 11-16.
39. Barker JN, Berth Jones J, Groes R et al. Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3.microg/g ointment. J Dermatolog Treat 2003; 14: 14-21.
40. Gerritsen MJ, van de Kerkhof PCM, Langner A. Long-term safety of topical calcitriol 3.microg/g ointment. Br J Dermatol 2001; 144 (Suppl. 58): 17-19.
41. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistance of treatment effect than betamettasone diproprionate in topical psoriasis therapy. J Dermatol Treat 2003; 14: 8-13.
42. Baadsgaard O, Traulsen J, Roed-Petersen J, Jakobsen HB. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatolog Treat 1995; 6: 145-150.
43. van de Kerkhof PC, Werfel T, Haustein UF et al. Tacalcitol ointment in the treatment of psoriasis vulgaris: A multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 2002; 135: 758-765.
44. Scarpa C. Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Acad Dermatol Venereol 1996; 6: 142-146.
45. Nishimura M, Hori YS, Nakimizo Y. Topical 1,24 dihydroxy-vitamin D 3, for the treatment of psoriasis. A review of the literature. European J Dermatol 1993; 3: 255-261.
46. van de Kerkhof PCM, Berth Jones J, Griffiths CE et al. Long-term efficacy and safety of tacalcitol ointment in patients with chrome plaque psoriasis. Br J Dermatol 2002; 146: 414-422.
47. Ruzicka T, Trompke C. Treatment of scalp psoriasis; an effective and safe tacalcitol emulsion. Hautarzt 2004; 55: 165-170.
48. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC903). Arch Dermatol 1989; 125: 1647-1652.
49. Dubertret L, Wallach D, Souteyrand P et al. Efficacy and safety of calcipotriol (MC903) ointment in psoriasis vulgaris. J Am Acad Dermatol 1992; 27: 983-988.
50. Pariser MD, Pariser RJ, Breneman D et al. Calcipotriene ointment applied once a day for psoriasis: A double-blind multicenter placebo-controlled study. Arch Dermatol 1996; 132: 1527 (letter).
51. Kragballe J, Gjertsen BT, De Hoop D et al. Double blind, right-left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193-196.
52. Cunliffe WJ, Claudy A, Fairiss G et al. A multicentre comparative study of calcipotriol and betamethasone 17-valerate in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26: 736-743.
53. Lebwohl M, Siskin SB, Epinette W. A multicenter trial of calcipotriol ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35: 268-269.
54. Guenther L, van de Kerkhof PC, Snellmann E et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized double-blind, vehicle-controlled clinical trial. B J Dermatol 2002; 147: 316-323.
55. Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriene/ betamethasone dipropionate formulation (™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393.
56. Douglas WS, Poulin Y, Decroix J et al. A new calcipotriol/betamethasone formulation (Daivobet) with rapid onset of action was superior to betamethasone dipropionate (Diprosone) and calcipotriol (Daivonex) in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-135.
57. Papp KA, Guenther L, Boyden B et al. Early onset of action and efficacy of a combination of calcipotrione and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48-54.
58. Fleming C, Lopez Estebaranz JL, Lui H, Loconsole F, Bellino M, Vena GA. Daily treatment regimens with calcipotriene/betamethasone dipropionate ointment and calcipotriene ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-1173.
59. Ortonne J, Kaufmann R, Lecha M, Seafield M. Efficacy of the treatment with calcipotriol/betamethasone dipropionate is followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomized double blind trial. Dermatology 2004; 209: 308-313.
60. van de Kerkhof PCM. The impact of a two compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: A randomize controlled trial. Br J Dermatol 2004; 151: 663-668.
61. Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of calcipotriol/betamethasone dipropionate two-compound product in the treatment of psoriasis. Br J Dermatol 2006; 154: 1150-1160.
62. Bourke JF, Featherstone S, Iqbal SJ, Hutchinson PE. A double-blind comparison of topical calcitiol (3 μg/g) and calcipotriol (50 μg/ g) in the treatment of chronic plaque psoriasis vulgaris. Br J Dermatol 1995; 133: 17 (Abstract).
63. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997; 137: 581-586.
64. Rappersberger K, Meingassner JG, Fialla R et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996; 106: 701-710.
65. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141: 103-107.
66. Mrowietz U, Graeber M, Brautigam M et al. A novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-996.
67. Zonneveld I, Rubins A, Jablonska S et al. Topical Tacrolimus is not effective in chronic plaque psoriasis. Arch Dermatol 1998; 134: 1101-1102.
68. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003; 83: 351-353.
69. Carrol ChL, Clarke J, Camacho F, Balkrishnan R, Feldman S. Topical Tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005; 141: 43-46.
70. Lebwohl M, Freeman AK, Chapman S et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-730.
71. Gribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-738.
72. Paramsothy Y, Collins M, Lawrence CM. Effect of UVB therapy and coal tar bath on short contact dithranol treatment for psoriasis. Br J Dermatol 1988; 118: 783-789.
73. McBride SR, Walker P, Reynolds NJ. Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: A randomized, within-patients controlled trial. Br J Dermatol 2003; 149: 1259-1264.
74. Storbeck K, Holzle E, Schurer N, Lehmann P, Plewig G. Narrow-band UVB (311 nm) versus conventional broad band UVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 1993; 28: 227-231.
75. Lebwohl M, Berman B, France DS. Addition of short contact anthralin therapy to an ultraviolet B phototherapy regimen: Assessment of efficacy. J Am Acad Dermatol 1985; 13: 780-784.
76. Monk BE, Hehir ME, Clement MI, Pembroke AC, du Vivier A. Anthralin-corticosteroid combination therapy in the treatment of chronic plaque psoriasis. Arch Dermatol 1988; 124: 548-550.
77. Grattan CE, Christophers AP, Robinson M, Cowan MA. Double-blind comparison of a dithranol and steroid mixture with a conventional dithranol regimen for chronic plaque psoriasis. Br J Dermatol 1988; 119: 623-626.
78. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: Comparison of maintenance treatments. Int J Dermatol 2001; 40: 64-66.
79. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000; 43: S43-S46. Review.
80. Lebwohl M, Poulin Y. Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol 1998: 39: S139-S143. Review.
81. Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: A randomized double-blind placebo study in severe psoriasis. Eur J Dermatol 1993; 3: 351-354.
82. Ramsay CA, Schwartz BE, Lowson D et al. Calcipotriol cream combined with twice weekly broad band UVB phototherapy: A safe, effective and UVB-sparing anti-psoriatic combination treatment. Dermatology 2000; 200: 17-24.
83. Grossman RM, Thivolet J, Claudy A et al. A novel therapeutic appreoach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31: 68-74.
84. van de Kerkhof PCM, Cambazard F, Hutchinson PE et al. The effect of addition of calcipotriol ointment (50vμg/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138: 84-89.
85. de Jong EMGJ, Mork NJ, Seyger MM et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003; 148: 318-325.
86. Griffiths CEM, Christophers E, Barker JNWN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-262.